Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

FTSE 100 ends week lower after week AstraZeneca, RBS results

share with twitter share with LinkedIn share with facebook
share via e-mail
02/14/2020 | 12:30pm EST
FILE PHOTO: The London Stock Exchange Group offices are seen in the City of London, Britain

UK blue-chip shares fell for a second day on Friday after AstraZeneca and RBS reported underwhelming results, while investors remained unsettled because of concerns over the impact of the coronavirus outbreak on the global economy.

The FTSE 100 index ended the Valentine's Day trading session 0.6% lower, down 0.8% for the week, while the midcap bourse rose 0.5% as it drew strength from the pound.

Global markets are expecting stimulus from central banks as new coronavirus showed no signs of peaking. U.S. Federal Reserve Chair Jerome Powell had last week warned that the economic impact from the outbreak could spill over globally.

The FTSE 100, with its larger exposure to commodity prices, has lagged its European counterpart, which has hovered at record high levels for most of the week, as investors shrugged off fears over the new virus.

London's main index has also been derailed as commodity prices take a hit from slower demand from China post the health crisis.

Among corporate news, AstraZeneca dropped over 4.3% as its quarterly earnings failed to match up to market expectations.

"Corporate updates triggered the declines in the pharma sector as well as the banking industry. Dealers are still worried about the health emergency in China as the situation isn't showing any signs of improving," CMC Markets analyst David Madden, said.

Royal Bank of Scotland fell 6.8%, ending the day at the bottom of the bluechip index, after its new top boss set out a new strategy that included cutting back the size of its loss-making investment bank and renaming the company NatWest.

"Every rose has its thorn; scratch beneath every RBS quarterly update and you'll find a sting or two," Markets.com analyst Neil Wilson wrote in note.

Warehousing specialist Segro outperformed the index, rising 1.5% and hitting a fresh high after it reported a jump in full-year profit and increased its dividend.

Among smaller stocks, biotechnology company Novacyt jumped 29% after it said it would launch a certified test for the new coronavirus next week.

Mosman Oil and Gas tanked 36% after it announced capital raise and updated the markets on its corporate strategy, which included the sale of some of its projects.

By Muvija M and Shashwat Awasthi

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.52% 7410 Delayed Quote.-4.05%
CMC MARKETS PLC 0.00% 155 Delayed Quote.5.73%
FTSE 100 INDEX 0.28% 7234.11 End-of-day quote.0.00%
LONDON BRENT OIL -2.62% 53.44 Delayed Quote.-13.77%
MOSMAN OIL AND GAS LIMITED 0.00% 0.145 Delayed Quote.-36.96%
NOVACYT -5.59% 1.52 Real-time Quote.852.66%
SEGRO PLC -0.49% 882 Delayed Quote.-0.82%
THE ROYAL BANK OF SCOTLAND GROUP PLC -1.05% 193.05 Delayed Quote.-18.81%
THORN GROUP LIMITED -5.00% 0.19 End-of-day quote.-4.76%
WTI -3.23% 48.56 Delayed Quote.-12.86%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA PLC
07:56aRedHill Biopharma Acquires Rights to Movantik from AstraZeneca
02/25REDHILL BIOPHARMA : AstraZeneca divests global rights to Movantik; License to Re..
02/25AstraZeneca to Sublicense Global Rights to Movantik to RedHill Biopharma
02/25ASTRAZENECA : divests global rights to Movantik
02/24China's CMC Capital raises over $950 million in its biggest private equity fu..
02/20EXCLUSIVE : Canadian regulator considers changes to new drug pricing plan
02/18Consumer groups, unions oppose fix for planned merger of AbbVie and Allergan
02/17ASTRAZENECA PLC : - Full-year and Q4 2019 results
02/14Health Care Flat Amid Mixed Earnings Season -- Health Care Roundup
02/14EUROPE : European shares settle below record highs
More news
Financials (USD)
Sales 2020 27 085 M
EBIT 2020 7 433 M
Net income 2020 2 990 M
Debt 2020 13 237 M
Yield 2020 3,00%
P/E ratio 2020 39,4x
P/E ratio 2021 28,1x
EV / Sales2020 5,09x
EV / Sales2021 4,57x
Capitalization 125 B
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 107,19  $
Last Close Price 94,91  $
Spread / Highest target 45,9%
Spread / Average Target 12,9%
Spread / Lowest Target -21,4%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Marcus Wallenberg Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC-4.05%124 604
JOHNSON & JOHNSON0.03%381 112
ROCHE HOLDING AG5.13%287 430
MERCK AND COMPANY-11.74%204 366
NOVARTIS-5.57%201 414
PFIZER-11.51%187 773